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2 AMERICAN JOURNAL OF MEDICAL GENETICS PART BExtinction learning is an importantmechanism in the successful
psychological treatment of anxiety. Individual differences in
response and relapse followingCognitive Behavior Therapymay
in part be explained by variability in the easewithwhich fears are
extinguished or the vulnerability of these fears to re-emerge.
Given the role of the endocannabinoid system in fear extinction,
this study investigates whether genetic variation in the endo-
cannabinoid system explains individual differences in response
to CBT. Children (N¼ 1,309) with a primary anxiety disorder
diagnosis were recruited. We investigated the relationship
between variation in the CNR1, CNR2, and FAAH genes and
change in primary anxiety disorder severity between pre- and
post-treatment and during the follow-up period in the full
sample and a subset with fear-based anxiety disorder diagnoses.
Change in symptom severity during active treatment was nomi-
nally associated (P< 0.05) with two SNPs. During the follow-up
period, five SNPs were nominally associated with a poorer
treatment response (rs806365 [CNR1]; rs2501431 [CNR2];
rs2070956 [CNR2]; rs7769940 [CNR1]; rs2209172 [FAAH])
and one with a more favorable response (rs6928813 [CNR1]).
Within the fear-based subset, the effect of rs806365 survived
multiple testing corrections (P< 0.0016).We found very limited
evidence for an association between variants in endocannabi-
noid system genes and treatment response once multiple testing
corrections were applied. Larger, more homogenous cohorts are
needed to allow the identification of variants of small but
statistically significant effect and to estimate effect sizes for
these variants with greater precision in order to determine their
potential clinical utility.
 2016 The Authors. American Journal of Medical Genetics Part B: Neuropsy-
chiatric Genetics Published by Wiley Periodicals, Inc.
Key words: anxiety; endocannabinoids; fear extinction;
Cognitive Behavior Therapy; childrenINTRODUCTION
Childhood anxiety disorders are very common [Kessler et al., 2005]
and are associated with a wide range of impairments [Kim-Cohen
et al., 2003; Erath et al., 2007; Asendorpf et al., 2008]. Response to
Cognitive Behavior Therapy (CBT) varies substantially between
patients [James et al., 2013]. Identifying predictors of response is
important given the potential for clinicians to identify children and
adolescents at risk for poorer outcomes before treatment begins and
to help inform the development of more efficacious therapies.
Recent years have seen a growing interest in the genetic prediction
of response to psychological therapy, a field known as therapyge-
netics [Lester and Eley, 2013]. Yet to receive attention is the
endocannabinoid (ECB) system, despite a growing literature impli-
catingendocannabinoids in thepathogenesisof anxietyand fear, fear
extinction, and emotional processing [Lafenetre et al., 2007; Hillard
et al., 2012; Ruehle et al., 2012; Mechoulam and Parker, 2013].
Extinction learning is assumed to be an important component of
CBT, in which individuals are repeatedly exposed to their feared
object, situation, or anxiety-provoking thought in the absence of
any aversive consequences. Over successive exposures, the patientlearns that their feared object is not predictive of an aversive
outcome and anxiety is reduced [Craske et al., 2014]. However,
extinguished fears are vulnerable to recovery and can re-emerge
with the passage of time, which creates limitations on the potential
durability and effectiveness of CBT [Craske et al., 2008; Arch and
Craske, 2009]. This is because extinction is a new learning process
that involves the encoding of a new competing memory, but which
does not replace the original fear memory, leaving it potentially
ready to re-emerge [Bouton, 2002]. A feature of anxiety disorders
both in adult and child samples is their tendency to recur even
following initially successful treatment with relapse rates reported
to approximate 20–30% in child and adolescent samples [Gearing
et al., 2013; Piacentini et al., 2014]. Surprisingly, little is known
about predictors of relapse. One possibility is that individual
differences in the ease with which fears are extinguished and/or
vulnerability of extinguished fears to re-emergemay in part explain
inter-individual variation in initial response and risk of relapse
following CBT.
The ECB system comprises of cannabinoid receptors (CB1 and
CB2), the endogenous endocannabinoids (anandamide [AEA] and
2-arachidonoylglycerol [2-AG]), and the catabolic enzymes for
endocannabinoid degradation (fatty acid amide hydrolase [FAAH]
for AEA and monoacylglycerol lipase [MAGL] for 2-AG). Consid-
erable research supports the hypothesis that endogenous endo-
cannabinoid signaling regulates anxiety. There is also suggestive
evidence that targeting components of the ECB system via activa-
tion of CB1 receptors or by manipulating FAAH activity may
produce anxiolytic effects [Kathuria et al., 2003; Lafenetre et al.,
2007; Gunduz-Cinar et al., 2013]. Pertinent to our understanding
of the factors influencing treatment response is research in adults
demonstrating the role of the ECB system in fear extinction
[Gunduz-Cinar et al., 2013]. Failure to effectively extinguish
fear when cues that previously predicted threat are no longer
present can lead to the maintenance of fear and has been proposed
as an important mechanism in the etiology of anxiety disorders
[Hofmann, 2008].
Animal research has shown that genetic deletion and pharma-
cological blockade of CB1 receptors impedes extinction [Marsi-
cano et al., 2002; Lafenetre et al., 2007]. In contrast, enhancing
cannabinoid neurotransmission using either anandamide reuptake
inhibitors, which alter FAAH activity or direct CB1 agonists
facilitates fear extinction [Chhatwal et al., 2005; Pamplona et al.,
2006; Bitencourt et al., 2008]. The ECB system may be particularly
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ories [Suzuki et al., 2008] thus attenuating the spontaneous
recovery of conditioned fear responding. Two studies, one [Rabi-
nak et al., 2013], which administered tetrahydrocannabinol (THC)
pre-extinction, and a second [Das et al., 2013] that administered
cannabidiol after extinction learning found consolidation of ex-
tinction learning to be enhanced in human participants. However,
a third study [Klumpers et al., 2012], which also administered THC
did not detect an effect of THC on consolidation of fear extinction.
Several studies have also shown that administration of cannabinoid
system modulators, such as THC, modulates the neural substrates
(amygdala, ventromedial prefrontal cortex, hippocampus) in-
volved in extinction learning, extinction memory recall [Rabinak
et al., 2014], and the processing of emotional stimuli [Phan et al.,
2008; Fusar-Poli et al., 2009; Bossong et al., 2013]. Given these
findings, cannabinoid-based pharmacotherapy and augmentation
of existing treatments has been proposed as a promising avenue for
the development of novel treatments for anxiety disorders
[Domschke and Zwanzger, 2008; Graham and Milad, 2011; Fitz-
gerald et al., 2014], although as of yet the evidence for efficacy
remains unclear [Whiting et al., 2015].
Recent research has investigated the effects of genetic variability
in human endocannabinoid signaling for fear extinction. Numer-
ous single nucleotide polymorphisms (SNPs) have been identified
in CNR1 and CNR2, the genes that encode for cannabinoid
receptor 1 and 2, respectively and in FAAH, the gene that encodes
for the FAAHprotein, the primary regulator of AEA signaling in the
brain [Cravatt et al., 2001]. Variation in rs2180619, a SNP in the
promoter region of CNR1 has been associated with fear extinction.
G allele carriers demonstrated robust extinction of fear evidenced
by a reduction in fear-potentiated startle relative to AA homozy-
gote carriers who failed to extinguish fear [Heitland et al., 2012]. A
small number of variants in CNR1 (e.g., rs1049353; rs806368) and
CNR2 (rs2501431) have been investigated in the context of emo-
tional processing of socially relevant stimuli [Chakrabarti et al.,
2006; Domschke et al., 2008] and in predicting antidepressant
treatment response in patients with Major Depression [Domschke
et al., 2008; Mitjans et al., 2012, 2013].
Research in mice has shown that FAAH inhibitors facilitate
extinction by augmenting AEA signaling in the amygdala. Simi-
larly, healthy carriers of the low-expressing A allele at rs324420,
which leads to reduced expression of FAAH and elevated levels of
AEA showed reduced amygdala activity [Hariri et al., 2009].
Furthermore, low expressing A allele carriers showed more rapid
habituation of amygdala responses to threatening stimuli relative
to CC homozygotes [Gunduz-Cinar et al., 2013]. They also
reported lower scores on a personality measure of stress reactivity
[Gunduz-Cinar et al., 2013]. A recent study showed persuasive
convergent effects of FAAH variation in both humans and mice.
Human A allele carriers showed enhanced fear extinction indexed
by reduced skin conductance response to the extinguished cue and
lower levels of trait anxiety.Mice carrying theA allele demonstrated
reduced freezing behavior on presentation of the extinguished cue
and decreased anxiety in response to two measures of anxiety-like
behaviors that involved placing the mice in conflict situations
(elevated plus maze test and novelty induced hypophagia test)
[Dincheva et al., 2015]. These findings suggest that variation inFAAH may be an important moderator of anxiety-related behav-
iors and is a plausible candidate for involvement in determining for
whom psychological treatments involving exposure components
will be most effective.
In the current study, we tested the association between poly-
morphisms of the CNR1, CNR2, and FAAH genes and response to
CBT in children and adolescents with an anxiety disorder diagno-
sis. To our knowledge, this is the first study to investigate genetic
variation in the endocannabinoid system and response to a psy-
chological treatment.We began by testing our hypotheses in a large
sample of children (N¼ 1,309) experiencing the full range of
anxiety disorder diagnoses and who had received a course of
CBT in order tomaximize power to detect genetic effects. However,
one possibility is that extinction learning may be implicated more
or less in the mechanisms of treatments for different disorders. For
example, extinction learning may be of greater relevance for the
successful treatment of predominantly fear based disorders such as
specific phobias and to a lesser extent for distress based disorders
like generalized anxiety disorder [Borkovec and Ruscio, 2001].
Thus, in secondary analyses, we tested our hypotheses in a subset of
the sample (N¼ 749) that had received a fear-based anxiety
disorder diagnosis (e.g., specific phobia, social phobia, separation
anxiety disorder, panic disorder). Theses analyses were informed
by research using genetic and phenotypic data to determine the
structure of psychopathology [Lahey et al., 2004; Clark and Wat-
son, 2006; Watson et al., 2008] and which suggests that emotional
disorders can be decomposed into distress disorders (e.g., major
depression, generalized anxiety disorder, posttraumatic stress dis-
order); fear disorders (e.g., phobias, panic disorder); and the
bipolar disorders [Watson et al., 2008].
We tested two hypotheses. Firstly, that genetic variation in
CNR1, CNR2, and FAAH would be significantly associated with
change in symptom severity from baseline to post-treatment
reflecting the influence of genetic variation in the ECB system
during the active treatment period. One possibility is that any effect
of ECB genes on early symptom change may reflect the role of the
ECB system in the extinction of fear. Second, we examined whether
ECB genetic variation was associated with change in symptom
severity from post-treatment to follow-up reflecting the influence
of ECB genetic variation onmaintenance of treatment gains.While
for some, this will reflect a period in which they continue to
consolidate the gains made during treatment, for others this
may reflect a period in which they begin experiencing a relapse
of symptoms. One possibility is that any effect of ECB genes on
symptom change and specifically the continuance of treatment
gains during the follow-up period may reflect the role of the ECB
system in the maintenance of extinction memories.
MATERIALS AND METHODS
Participants
Participants were recruited for the Genes for Treatment Study
(GT) study, a multi-site international collaboration designed to
identify clinical, demographic and genetic predictors of outcome
following CBT for anxiety disorders in children and adolescents
[Hudson et al., 2015]. The sample comprised 1,309 individuals for
whom treatment response data was available at the post and/or
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more SNPs. Participants were 5–17 years of age (89.6% aged 5–12
years, mean age: 9.81 years, 52% female) and met DSM-IV criteria
for primary diagnosis of an anxiety disorder. Exclusion criteria
comprised significant physical or intellectual impairment, psycho-
ses, and concurrent treatment. Participants completed a course of
CBT as part of a trial or as treatment as usual at one of eleven sites:
Sydney, Australia (n¼ 641); Reading andOxford,UK (n¼ 302 and
n¼ 15); Aarhus, Denmark (n¼ 123); Bergen, Norway (n¼ 39);
Groningen, The Netherlands (n¼ 36); Bochum, Germany
(n¼ 52); Florida, US (n¼ 38); Basel, Switzerland (n¼ 47), Cam-
bridge, UK (n¼ 12); and Amsterdam, The Netherlands (n¼ 4). All
treatments were manualized and treatment protocols across sites
were comparable for core elements of CBT including teaching of
coping skills, cognitive restructuring, and exposure. Three broad
groups of treatment modality were given: individual CBT (27.4%),
group based CBT (52.8%), and parent-supported guided self-help
CBT (19.9%). Follow-up data was collected at three (n¼ 231), 6
(n¼ 675), or 12-months (n¼ 250) after cessation of treatment.
Further sample characteristics for the full sample are given in
Table I and site-specific trial information is given in the supple-
mentary information accompanying this article. Sample character-
istics for the subset with a fear-based diagnosis (excluding
Generalized Anxiety Disorder (GAD), Obsessive Compulsive
Disorder (OCD), Post Traumatic Stress Disorder (PTSD), Anxiety
Disorders NotOtherwise Specified (ADNOS)) are given in Table SI
in the supplementary materials.Measures
Diagnoses were made using the Anxiety Disorders Interview
Schedule for DSM-IV (ADIS-IV-C/P) [Silverman and Albano,
1996] at all sites except for Bochum and Basel where the German
equivalent Kinder-DIPS was used [Schneider et al., 2009]. Clinical
Severity Ratings (CSRs) ranged from 0 to 8 and were based on
composite parent and child reports (see Hudson et al., 2015, for
further details). Treatment response was assessed as change in
primary diagnosis severity from pre-treatment to post-treatment
and from post-treatment to follow-up. A diagnosis was assigned
when the childmet diagnostic criteria and received aCSR of four or
greater. Primary diagnoses included Generalized Anxiety Disorder
(GAD; 37.7%), Separation Anxiety Disorder (SAD; 21.7%), Social
Anxiety Disorder (21.3%), Specific Phobia (11.4%), or Panic
Disorder, Obsessive Compulsive Disorder, Post Traumatic Stress
Disorder, Selective Mutism,1 or Anxiety Disorders Not Otherwise
Specified (other anxiety disorders; 7.9%).Genotyping
DNA was collected using buccal swabs or Oragene saliva samples
(DNAGenotek, Ottawa, Canada). Buccal swab DNAwas extracted
using established procedures designed to maximize the purity and
yield of the sample [Freeman et al., 2003]. DNA from saliva samples1In cases with primary selective mutism, a diagnosis of severe social phobia was
also given. The selective mutism was considered by the clinician to be primary,
the most interfering.was extracted using Prep-it.L2P according to the manufacturers
protocol (DNA Genotek). Sample preparation prior to genotyping
is described elsewhere [Coleman et al., 2016]. In brief, samples were
subjected to ultrafiltration and resuspension to increase DNA
concentration and included in genotyping if the resulting concen-
tration exceeded 50 ng/ul.
Genotypes for seven CNR1 polymorphisms (rs2180619;
rs1049353; rs806368; rs806371; rs806379; rs1535255; rs806369),
one CNR2 polymorphism (rs2501431) and one FAAH polymor-
phism (rs324420) drawn from the candidate gene literature on fear
extinction, emotional processing, and response to antidepressant
treatment were genotyped by LGC Genomics (Hoddesdon, UK)
using validated arrays with KASP technology or were obtained
from the Illumina Core Exome-12v1.0microarray. Four additional
markers, which were genotyped using both platforms showed an
average of 98% consensus on genotype calls.
For the subset of the sample with array data (n¼ 980) additional
genotypes were available for 123 CNR1 polymorphisms, 159 CNR2
polymorphisms, and 318 FAAH polymorphisms. Array data was
included in all analyses to provide LD context for multiple testing
corrections and to provide more accurate gene-based tests of
association.
Quality control and imputation procedures for those samples
with microarray data are provided in full elsewhere [Coleman
et al., 2016]. Briefly, common variants (minor allele frequency
>5%) were included in the analyses if they were genotyped in
>99% of samples and if they did not deviate substantially from
Hardy–Weinberg equilibrium (HWE test P-value> 105). SNPs
were included if they could be imputed to the December 2013
release of the 1000 Genomes Project reference [1000Genomes-
Consortium, 2012] with >90% completeness, and an info metric
of >0.8 (a value ranging between 0 and 1 which indicates the
certainty with which the SNP has been imputed). Using these cut-
offs, data was available for 127 CNR1 SNPs, 160 CNR2 SNPs, and
318 FAAH SNPs. Gene coverage estimated using directly geno-
typed and imputed SNPsmeeting criteria for inclusionwas 11.5%,
19.8%, and 28.9% for CNR1, CNR2, and FAAH genes, respec-
tively. For each gene, analyzed variants were entered as tagging
SNPs in the Tagger utility of Haploview [Barrett et al., 2005]. All
common variants (MAF3 0.05) within and 100 kb of the gene
boundaries (as listed in HapMap release IIþ III) were in linkage
disequilibrium (r2> 0.8) with at least one tagging SNP. This
indicates good coverage of all linkage regions across the genes
studied. To account for patterns of linkage disequilibrium (LD)
between SNPs, LD based clumping was performed for each
analysis to reduce the SNP set to a smaller number of clumps
of correlated SNPs.Ethical Approval
Each site had trial-specificHuman Ethics and Biosafety Committee
approval for the collection of biological samples with the research
conducted in accordance with the Declaration of Helsinki. In all
instances parents provided written informed consent, children
assent. The storage and analysis of DNA was approved by the
King’s College London Psychiatry, Nursing and Midwifery Re-
search Ethics Sub-Committee.
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Two outcome measures were considered in our primary analyses.
First, the change in severity (CSR score) of the primary anxiety
diagnosis from baseline to post-treatment, reflecting the active
treatment period. Second, the change in severity of the primary
anxiety diagnosis from post-treatment to follow-up time points,
reflecting a period of consolidation or risk for relapse.
Linear mixed effects models were performed to investigate the
effect of ECB polymorphisms on change in severity (CSR score) of
the primary anxiety disorder diagnosis. All genotypeswere coded to
reflect an additive model where 1, common homozygote; 0,
heterozygote; and 1, rare homozygote. To make use of all available
post baseline measurements and provide estimates in the presence
ofmissing data, the effects of predictors of response were estimated
using mixed models fitted with full maximum likelihood. All
models included either the fixed effects of baseline severity (CSR
of the primary anxiety disorder diagnosis at baseline, centred at the
mean) or post-treatment severity (CSR of the primary anxiety
disorder diagnosis at post-treatment, centred at the mean), age
(centred at the mean), and gender. Analyses investigating post to
follow-up change also included the linear and quadratic effects of
time to account for the curvilinear slope of treatment response
across this period. All models included the random effects of
individual to account for correlations between repeated measures
from the same individual. We also included a higher order random
effect of trial to account for between trial differences in outcome. As
each trial was conducted at a single site, this random effect also
accounted for between-site differences.
In all analyses, the beta values of variables predicting a more
favorable response to treatment or continued gains during the
follow-up period (i.e., greater reduction in severity) are negative,
while variables predicting a less favorable response are positive.
Analyses were performed in STATA version 12.0.
All analyses (baseline to post-treatment change, post-treatment
to follow-up change, fear-based diagnoses subset ((N¼ 749), gene-
based association tests) consider data from all available SNPs
including both directly genotyped SNPs available on the entire
sample (N¼ 1,309) and the additional SNPs available for the subset
of the sample with array data (n¼ 980). N’s are given for each
sentinel SNP in the corresponding table for each analysis.
Results from the initial association analyses were clumped
based on patterns of LD according to P-value using PLINK
[Purcell et al., 2007], thus reducing the SNP set to a smaller
number of correlated SNPs. Each independent clump was rep-
resented by a sentinel SNP (that with the lowest P-value in the
clump), and contained all SNPs in linkage disequilibrium with
the sentinel (R2> 0.25, within 250 kb of the sentinel). To correct
for multiple testing, revised significance thresholds were calcu-
lated based on the number of independent clumps identified for
each analysis.
Gene-based tests for association with response were performed
using VEGAS modified to use the hg19 genome build [Liu et al.,
2010]. Gene boundarieswere defined as the longest transcript of the
gene listed in the UCSC Genome Browser and variants considered
100 kb from each end. Linkage disequilibrium patterns were
calculated from the genotyped data.Power Calculations
Power calculations indicated that with a sample size of 980, we had
80% power to detect a variant with a minor allele frequency of 0.05
capturing 1.6%of variancewith a corrected alpha level of 0.017. For
variants explaining 0.1%, 0.5%, and 1% of the variance we had
1.6%, 18%, and 50% power, respectively.RESULTS
Clinical outcomes in the full sample were comparable to previ-
ously reported estimates [Hudson et al., 2013, 2015; James et al.,
2013]. Following treatment, 58% of the sample was free of their
primary anxiety disorder diagnosis with this rate rising to 67% by
follow-up. Symptom severity reduced significantly between base-
line (6.22) and post-treatment (2.97, t(1256)¼ 54.57, P< 0.0001)
and post-treatment and follow-up time points (2.42, t
(1256)¼ 9.40, P< 0.0001). We initially explored the effects of
clinical (baseline severity; primary diagnosis; treatment type) and
demographic factors (age; gender) on change in symptom severity
between baseline and post-treatment. Findings were broadly
similar to those reported for the full sample [Hudson et al.,
2015]. Individuals with Social Anxiety Disorder, Specific Phobias,
or Separation Anxiety Disorder showed a significantly poorer
response to treatment compared to those with Generalized Anxi-
ety Disorder (b¼ 0.24, P< 0.0001; b¼ 0.11, P¼ 0.005, and
b¼ 0.06, P¼ 0.044, respectively. Higher severity at baseline was
associated with significantly poorer response to treatment
(b¼ 0.30, P< 0.0001). However, treatment response did not
differ according to sex, age, or treatment type (all P values> 0.05).
For change in symptom severity between post-treatment
and follow-up time points, individuals with Specific Phobias
showed a significantly poorer treatment response compared to
those with Generalized Anxiety Disorder (b¼ 0.15, P¼ 0.011).
Higher severity at post-treatment was also associated with signifi-
cantly poorer response during the follow-up period (b¼ 0.19,
P< 0 .0001). Response during the follow-up period did not differ
according to sex, age, or treatment type (all P values> 0.05). A
highly similar pattern of results was observed when the sample was
restricted to those with a fear-based anxiety disorder diagnosis
only.Change in Symptom Severity From Baseline to
Post-Treatment: Analyses Using the Entire
Sample (N¼ 1,309)
Thirty independent clumps were identified based on patterns of
LD and were used to calculate adjusted P values for multiple
testing corrections (P< 0.0017). Each independent clump was
represented by a sentinel SNP (that with the lowest P-value in the
clump), and contained all SNPs in linkage disequilibrium with
the sentinel (R2> 0.25, within 250 kb of the sentinel). Two
independent clumps were nominally associated with response
(P< 0.05). An increasing number of copies of the minor allele of
rs12133557 was associated with a more favorable treatment
response (i.e., greater reductions in severity) across the treatment
period. In contrast, the minor allele of the sentinel SNP
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TABLE II. Independent Clumps Nominally Associated (P< 0.05) With Treatment Response Between (a) Baseline and Post-Treatment
and (b) Post-Treatment and Follow-Up
(a) Change in symptom severity from baseline to post-treatment
Sentinel SNP Gene Clump BP Minor allele MAF Info b 95% CI P na
rs12133557 CNR2 24191219–24223859 T 0.098 0.978 0.07 0.14 to
0.01
0.020 925
rs6454676 CNR1 88860482–88885426 A 0.104 0.977 0.07 0.002–
0.13
0.042 926
(b) Change in symptom severity from post-treatment to follow-up
Sentinel SNP Gene Clump BP Minor allele MAF Info b 95% CI P n
rs806365 CNR1 88843390–88845949 T 0.408 Genotyped
(microarray)
0.11 0.04–0.18 0.004 702
rs2501431 CNR2 24108683–24206032 G 0.423 Genotyped (LGC) 0.09 0.03–0.16 0.007 874
rs2070956 CNR2 24191219–24223859 C 0.101 0.995 0.14 0.02–0.26 0.021 698
rs6928813 CNR1 88860482–88885426 G 0.180 Genotyped
(microarray)
0.11 0.20 to
0.01
0.033 702
rs7769940 CNR1 88947649–88973751 T 0.209 Genotyped
(microarray)
0.10 0.01–0.19 0.034 702
rs2209172 FAAH 46938837–46978946 T 0.206 Genotyped
(microarray)
0.09 0.00–0.18 0.044 702
All genotypes were coded to reflect an additive model where 1, common homozygote; 0, heterozygote; and 1, rare homozygote.
Regression weights (b) significantly less than 0 indicate that an increasing number of copies of theminor allele of the SNP was associated with a greater reduction in symptom severity across the active
treatment or follow-up period. Values significantly greater than 0 indicate that an increasing number of copies of the minor allele of the SNP was associated with a poorer reduction in symptom severity.
an reflects total number of cases included in regression analysis for the sentinel SNP.
LESTER ET AL. 7rs6454676 (with this clump including the directly genotyped
rs1535255) was associated with a poorer treatment response
(i.e., smaller reductions in severity or an increase in severity
associated with increasing number of copies of the minor allele,
see Table II). However, neither of these effects survived multiple
testing corrections at P< 0.0017. The remaining SNPs all had P
values exceeding 0.05. Analyses restricted to a subset that identi-
fied as having four White European grandparents (n¼ 916) are
available in the supplementary materials. Gene based association
tests were non-significant (CNR1: P¼ 0.172; CNR2: P¼ 0.202;
FAAH: P¼ 0.846).Change in Symptom Severity From Baseline to
Post-Treatment: Fear-Based Anxiety Disorder
Diagnosis Subset (N¼ 749)
Twenty-nine independent clumps were identified based on pat-
terns of LD and were used to calculate adjusted P values for
multiple testing corrections (p< 0.0017). Two independent
clumps were nominally associated with response (P< 0.05) with
an increasing number of copies of the minor allele of the sentinel
SNP rs6454676 (with this clump including the directly genotyped
rs1535255) associated with a poorer treatment response (see
Table III). The minor allele of rs12133557 was associated with a
more favorable treatment response across the treatment period.
However, neither of these effects survived multiple testing correc-
tions. Gene based tests on this subset were non-significant (CNR1:
P¼ 0.129; CNR2: P¼ 0.148; FAAH: P¼ 0.694).Change in Symptom Severity From Post-
Treatment to Follow-Up
Thirty independent clumps were identified and were used to
calculate adjusted P values for multiple testing corrections
(P< 0.0017). Of these, five independent clumps were associated
with a poorer response (i.e., smaller reductions in severity or an
increase in severity associated with an increasing number of copies
of the minor allele) during the follow-up period at a nominal P-
value of < 0.05 (sentinel SNPs: rs806365; rs2501431; rs2070956;
rs7769940; rs2209172) while one independent clump (sentinel
SNP: rs6928813) predicted a more favorable response (i.e., greater
reductions in severity associated with increasing number of copies
of minor allele). All clumps with P< 0.05 are displayed in Table II.
However, none of the suggestively significant clumps survived
multiple testing correction (P< 0.0017) with rs806365 having
the lowest P-value at P¼ 0.004. Analyses restricted to a subset
that identified as having four White European grandparents are
available in the supplementary materials. Gene based association
tests on the full sample were all non-significant (CNR1: P¼ 0.360;
CNR2: P¼ 0.092; FAAH: P¼ 0.745).
Change in Symptom Severity From Baseline to
Follow-Up: Fear-Based Anxiety Disorder
Diagnosis Subset
Thirty-one independent clumps were identified and were used to
calculate adjusted P values for multiple testing corrections
(P< 0.0016). Of these, three independent clumps were associated
TABLE III. Independent Clumps Nominally Associated (P< 0.05) With Treatment Response Between (a) Baseline and Post-Treatment
and (b) Post-Treatment and Follow-Up in the Subset of the Sample With Fear-Based Anxiety Disorder Diagnoses (n¼ 749)
(a) Change in symptom severity from baseline to post-treatment
Sentinel SNP Gene Clump BP Minor allele MAF Info b 95% CI P na
rs12133557 CNR2 24191219–24223859 T 0.094 0.978 0.11 0.20 to 0.03 0.011 540
rs6454676 CNR1 88860482–88885426 A 0.108 0.977 0.09 0.005–0.17 0.038 539
(b) Change in symptom severity from post-treatment to follow-up
Sentinel
SNP Gene Clump BP Minor allele MAF Info b 95% CI P n
rs806365 CNR1 88843390–88845949 T 0.392 Genotyped
(microarray)
0.17 0.07–0.27 0.0011 399
rs7769940 CNR1 88947649–88973751 T 0.216 Genotyped
(microarray)
0.19 0.07–0.32 0.003 399
rs2501431 CNR2 24108683–24206032 G 0.448 Genotyped
(LGC)
0.14 0.04–0.23 0.004 495
All genotypes were coded to reflect an additive model where 1, common homozygote; 0, heterozygote; and 1, rare homozygote.
Effects that survived multiple testing corrections are highlighted in bold.
Regression weights (b) significantly less than 0 indicate that an increasing number of copies of the minor allele of the SNP was associated with a greater reduction in symptom severity across the active
treatment or follow-up period. Values significantly greater than 0 indicate that an increasing number of copies of the minor allele of the SNP was associated with a poorer reduction in symptom severity.
an reflects total number of cases included in regression analysis for the sentinel SNP.
8 AMERICAN JOURNAL OF MEDICAL GENETICS PART Bwith a poorer response (i.e., smaller reductions in severity or an
increase in severity associated with increasing number of copies of
the minor allele) during the follow-up period at a nominal P-value
of <0.05 (sentinel SNPs: rs806365; rs7769940; rs2501431, see
Table III). These same SNPs were nominally significant in the
analyses using the entire dataset. However, the effects were stronger
when examined in the subset of participants with fear-based
disorders, with the effect for rs806365 surviving multiple testing
corrections (P¼ 0.0011). Gene based tests on this subset were non-
significant (CNR1: P¼ 0.620 CNR2: P¼ 0.053; FAAH: P¼ 0.335).DISCUSSION
Given the potential role of the ECB system in fear extinction and the
maintenance of extinction memories, this study investigated
whether genetic variation in the CNR1, CNR2, and FAAH genes
was associated with response to CBT in children and adolescents
with an anxiety disorder. In our analyses, two SNPs (rs12133557
and rs6454676) were nominally associated (P< 0.05) with change
in symptom severity in both the entire sample and the subset with
fear based diagnoses. An increasing number of copies of the minor
allele of rs12133557 was associated with a more favorable response
during the active treatment period. In contrast, an increasing
number of copies of the minor allele of rs6454676 was associated
with a poorer response during the active treatment period. How-
ever, these effects did not survive stringent multiple testing cor-
rection in either the entire sample or subset restricted to fear-based
diagnoses only. Furthermore, we hypothesized that individual
differences in the continuation of treatment gains during the
follow-up period may be associated with genetic variation in
ECB genes. Six independent clumps were nominally associated
(P< 0.05) with change in symptom severity over the follow-up
period in the entire sample, five where an increasing number of
copies of the minor allele was associated with a poorer response(sentinel SNPs: rs806365; rs2501431; rs2070956; rs7769940;
rs2209172), and one with a more favorable response (sentinel
SNP: rs6928813). Again, none of these effects survived multiple
testing corrections. Three of these same sentinel SNPs were also
nominally associated with response in the fear-based subset
(rs806365; rs7769940; rs2501431). The effect size of these SNPs
was larger in the fear-based subset with the effect of rs806365
remaining significant after multiple testing corrections were ap-
plied. Gene based tests of association were all non-significant. In
summary, our findings suggest only very limited evidence for a role
of genetic variation in the ECB system in predicting individual
differences in response toCBT for anxiety disorders in children and
adolescents. Where these effects do exist they are very small and
appear to have greater predictive powerwhen examined in a sample
restricted to fear-based anxiety diagnoses only.
The strongest finding in our analyses was for SNP rs806365,
which was nominally associated with a poorer response during the
follow-up period in the full sample (P¼ 0.004) and remained
significantly associated after multiple testing correction in the
fear-based anxiety diagnosis subset (P¼ 0.0011). While not previ-
ously investigated with respect to anxiety linked traits or fear
extinction, this locus has shown preliminary evidence of associa-
tion with insulin resistance, risk for Type 2 diabetes and coronary
heart disease [de Miguel-Yanes et al., 2011]. Of greater relevance is
research suggesting that variation at this locus may be associated
with differential response to smoking cessation treatments and thus
it could be hypothesized, sensitivity to environmental influences
such as treatment regimens. For example, male carriers of one or
moreminor T alleles had increased rates of abstinence to treatment
with buproprion (a norepinephrine and dopamine reuptake in-
hibitor) and transdermal (patch) nicotine replacement therapy but
significantly decreased odds of abstinence in response to nicotine
nasal spray replacement therapy [Lee et al., 2012]. In the present
study, with each additional T allele, participants showed a signifi-
LESTER ET AL. 9cantly poorer response (a smaller reduction in severity) to treat-
ment across the follow-up period. This may indicate that T allele
carriers are less sensitive to any continuing effects of CBT beyond
the initial treatment period and ultimately may be placed at a
greater risk of relapse. One possible mechanism worthy of further
investigation is that this SNP (and the ECB system more broadly)
may be involved in the maintenance of extinction memories
beyond the active treatment period. While not possible in this
study, it would be of interest to observe whether T allele carriers are
at an increased risk of relapse with a longer follow-up assessment
period perhaps as a consequence of increased risk for spontaneous
recovery of conditioned fear responding.
None of the SNPs previously studied in candidate gene studies of
laboratory based fear extinction [Heitland et al., 2012; Dincheva
et al., 2015], emotional processing [Chakrabarti et al., 2006;
Domschke et al., 2008; Hariri et al., 2009; Gunduz-Cinar et al.,
2013] or response to antidepressant treatment [Domschke et al.,
2008;Mitjans et al., 2012, 2013], on which data was available in this
study, approached significance in either analysis. The only excep-
tion was rs2501431, a SNP in CNR2 that was previously studied in
relation to response to treatment with citalopram in a small sample
of outpatients with depression [Mitjans et al., 2012]. In this earlier
study, variation in rs2501431 was not associated with symptom
change in response to citalopram, but overall AA homozygotes
reported more severe depression across the entire treatment pe-
riod. In the present study, GGhomozygotes showed a less favorable
response (a smaller reduction in severity) during the follow-up
period, albeit only at a nominal level of significance. Unlike prior
research, there was no significant difference in severity of anxiety at
baseline or mean severity across the treatment and follow-up
period as a function of rs2501431 genotype. Differences in phe-
notype, sample type, treatment approach and sample size may
explain the inconsistency in direction of effects seen across this
study and that of Mitjans et al. [2012].
There are several explanations, which may in part account for
the lack of convincing significant findings in this study despite
encouraging experimental work for a role of genetic variation in
ECB genes in fear extinction and emotional processing. Firstly, the
CBT protocols given to participants, while strongly underpinned
by the principles of extinction through exposure, also comprised a
number of cognitive elements including teaching of coping skills
and cognitive restructuring. Inevitably, this creates a far noisier
analogue of the fear extinction paradigms used in the laboratory
environment, which may have reduced the ability to detect signifi-
cant effects. Furthermore, previous associations between variation
in CNR1 and FAAH and fear extinction have been observed in
response to short-term experimentally conditioned fears in adults
and not to clinical levels of anxiety in children and adolescents.
Nonetheless, stronger effects may have been observed on response
to a purer exposure-based treatment or with a sample that was less
heterogeneous with regard to anxiety diagnosis and treatment
modality. In particular, the present sample and our initial analyses
included the full range of anxiety disorder diagnoses. One possi-
bility is that extinction learning may be implicated more or less in
themechanisms of treatments for different disorders. For example,
extinction learning may be of greater relevance for the successful
treatment of predominantly fear based disorders such as specificphobias and to a lesser extent for distress based disorders like
generalised anxiety disorder [Borkovec and Ruscio, 2001]. A
secondary analysis performed in the subset of the sample restricted
to those with a fear-based anxiety diagnosis provides suggestive
evidence that this may be the case. The magnitude of effects was
somewhat stronger in this restricted sample with the effect of
rs806365 remaining significant even after multiple testing correc-
tions were applied (see Table III). Further research should also
establish a role for the ECB system in fear extinction in children and
adolescents given that all of the experimental and treatment
research to date has been with adult samples.
Secondly, any effects of ECB genetic variation on the mainte-
nance of treatment gains, or conversely relapse of symptoms, may
require a longer follow-up period to emerge (90% of the current
sample had a follow-up period of 6 months or less). The change in
symptom severity over the follow-up period was smaller and less
variable than that seen during the active treatment phase with 47%
of participants showing no change in symptom severity from post-
treatment to follow-up. Only a minority of participants (17%)
showed any worsening of symptoms over the follow-up period.
Thus, analyses of the follow-up period were limited by the reduced
variance in response.
A more general limitation of the present study is that it took a
candidate gene approach. However, this limitation was mitigated
by the inclusion of array data on a subset of the sample providing
more comprehensive coverage of the genes under investigation and
LD context for the calculation of multiple testing corrections.
Nonetheless within psychiatric genetics broadly, and the therapy-
genetics literature to date, candidate gene studies have often failed
to replicate, have typically reported very small effect sizes and are
sensitive to publication bias [Duncan and Keller, 2011; Lester and
Eley, 2013]. Nominating candidate genes for investigation requires
knowledge of the pathophysiology of the phenotype under inves-
tigation and the putativemechanisms through which CBTmay act.
Psychological treatment response is a complex trait and while
extinction learning is an important process underpinning CBT,
the etiology of treatment response is multifactorial. Thus, it is very
unlikely that any single genetic polymorphism within the ECB
system, or more generally, will explain a sufficiently large amount
of variance in response to be clinically meaningful. To date, the
strongest evidence for a role of the ECB system in fear extinction
has come from animal studies employing genetic deletion and
pharmacological modulation designs [Lafenetre et al., 2007]. Such
studies are more likely to show large and pervasive effects in
comparison to human genetic association studies, where the
biological effect of an individual variant in vivo is likely to be
very small. Despite being by far the largest therapygenetics study to
date, the present study was powered to detect a variant capturing
1.6% of variance in treatment response with 80% power but had
only 1.5% power to detect a variant of very small effect size
explaining 0.1% of variance. If the true effect of rs806365 lies
closer to the effect size of 0.0029% observed (in the full sample),
then this would require a sample of 5,435 to detect these effects at
a¼ 0.0017 with 80% power. Notwithstanding the huge expense
and effort that would be required to assemble samples of this
magnitude, such a small effect on its own is extremely unlikely to be
of any clinical utility.
10 AMERICAN JOURNAL OF MEDICAL GENETICS PART BGiven the challenges of candidate gene studies, it will become
increasingly important for the therapygenetics field to work col-
laboratively to assemble large datasets that can be used to both
study the mechanisms underlying CBT response and which will
allow us to exploit hypothesis-free whole genome based
approaches. These methods have the potential to identify novel
and unexpected variants associated with treatment response [Cole-
man et al., 2016]. In conjunctionwith statistical approaches such as
polygenic risk scoring, genome wide approaches allow the oppor-
tunity tomove beyond single variant approaches tomethodswhich
aggregate across a large number of markers in order to capture a
greater and ultimately clinically significant proportion of the
variance in outcome [Krapohl et al., 2015; Keers et al., 2016].
An interesting avenue for further research is to investigate epige-
netic and gene expression predictors and correlates of psychologi-
cal treatment response, as these approaches may allow us to get
closer to the biological mechanisms of CBT response. This work
while in its infancy has shown early promise [Perroud et al., 2013;
Roberts et al., 2014, 2015; Yehuda et al., 2015]. Of relevance, a
recent study investigating gene expression change in response to
exposure-basedCBT for anxiety disorders reported that an increase
in DALGB gene expression (diacylglycerol lipase beta gene), which
is involved in the biosynthesis of 2-AG (an endogenous endocan-
nabinoid), was associated with greater reductions in severity while
a reduction in DALGB expression corresponded with lower reduc-
tions in severity [Roberts et al., 2016]. This finding is consistent
with research showing that increased levels of 2-AG (an endoge-
nous endocannabinoid) are associated with anxiolytic effects
[Gunduz-Cinar et al., 2013].
In summary, this is the first study to investigate the role of
genetic variation in the endocannabinoid system and response to
psychological therapy for anxiety disorders. A small number of
genetic variants were nominally associated with individual differ-
ences in treatment response during the active treatment and follow-
up period. Only one of these effects remained significant after
multiple testing corrections and in a sample restricted to those with
a fear-based anxiety disorder diagnosis. The ECB system remains a
plausible target for involvement in response to psychological
therapies underpinned by the principles of extinction learning.
However, the effect of any single variant is likely to be very small
given the complexity and multitude of mechanisms underpinning
response to psychological treatments. The use of larger samples
with greater statistical power and more homogeneous samples
which reduce noise in the data would allow us to estimate the effect
size of any variant with greater precision. Notwithstanding this,
there are potentially large benefits for patients and wider society in
knowing more about what determines who responds well to
psychological therapies, and why. Thus, therapygenetics remains
an important area for further research.ACKNOWLEDGMENTS
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